Posted by Michael Wonder on 21 Apr 2020
Andexanet alfa for reversing anticoagulation
21 April 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using andexanet alfa in the NHS in England.
The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees and commentators, clinical experts and patient experts.
Andexanet alfa is not recommended, within its marketing authorisation, for reversing anticoagulation with apixaban or rivaroxaban in adults with uncontrolled or life-threatening bleeding.
